BioSpace News Archive

Business

Lilly Bets $630M on Pain Target Novartis Failed

Eli Lilly is expanding its pain management pipeline with a new asset from Belgium-based Confo Therapeutics targeting the angiotensin II type 2 receptor.

March 2, 2023
·
2 min read
·
Kate Goodwin
Business

George Church-Backed Thymmune Launches to Target Overlooked Organ

Thymmune is backed by an A-list team of investors including Pillar VC, former Alnylam CEO John Maraganore and famed geneticist George Church.

March 2, 2023
·
2 min read
·
Tristan Manalac
Is a 4-Day Workweek Possible for Biopharma?

Results from the largest-ever trial of a four-day workweek showed overwhelming success, but is that success possible for biopharma companies?

March 2, 2023
·
3 min read
·
Christie Adams and Rosemary Scott
Job Trends

Novo Boosts Boston R&D Operations, Adds 200+ Jobs with New R&D Site

Novo Nordisk announced Thursday it plans to expand its research and development operations in the greater Boston area and add over 200 new jobs this year.

March 2, 2023
·
2 min read
·
Tristan Manalac
Business

MorphoSys Cuts Pre-Clinical Programs, 17% of Staff

MorphoSys AG announced Thursday it plans to drop its pre-clinical programs and cut 17% of its workforce in an effort to extend its cash runway.

March 2, 2023
·
1 min read
·
Kate Goodwin
Santhera Submits Marketing Authorization Application to the UK MHRA for Vamorolone in Duchenne Muscular Dystrophy

Santhera Pharmaceuticals announces that it has submitted a marketing authorization application to the UK Medicines and Healthcare products Regulatory Agency for vamorolone for the treatment of Duchenne muscular dystrophy.

March 2, 2023
·
6 min read
Zealand Pharma convenes its Annual General Meeting 2023

Company Announcement – No. 2 / 2023 Zealand convenes its Annual General Meeting 2023.

March 2, 2023
·
1 min read
Valneva Provides Clinical and Regulatory Updates for its COVID-19 Vaccine VLA2001

Valneva SE, a specialty vaccine company, announced additional data from remaining clinical studies and an update on regulatory submissions for its inactivated COVID-19 vaccine, VLA2001.

March 2, 2023
·
7 min read
Business

argenx Reports Full Year 2022 Financial Results and Provides Fourth Quarter Business Update

argenx reported financial results for the full year 2022 and provided a fourth quarter business update.

March 2, 2023
·
15 min read
Business

argenx Announces Planned Transition of Chief Operating Officer

argenx, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that Karen Massey will join argenx as Chief Operating Officer, effective March 13, 2023.

March 2, 2023
·
5 min read